US clears Pfizer’s biosimilar or Epogen, Procrit
The US Food and Drug Administration has approved Pfizer’s Retacrit, a biosimilar of Amgen’s Epogen and Johnson & Johnson’s Procrit.
Read More
Tag: Procrit
Pfizer’s Epogen/Procrit biosimilar wins US backing
Pfizer’s biosimilar of Amgen’s epoetin alfa (Epogen/Procrit) has won backing in the US for approval across all proposed indications.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
